SignalRx Pharmaceuticals Inc.
San Diego, CA · CIK 0001974464 · Biotech · Private
SRX, a third-generation covalent small-molecule inhibitor targeting BTK, PI3K, and BRD proteins for B-cell malignancies
signalrx.com →- Grants
- $5.9M
- 10 awards
- Sector median: 1
- Raised
- $250K
- 1 Form D · May 2023
- 41 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 15
- 8 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors | $209,001 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors | $299,738 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors | $299,738 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | $1,968,269 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | $1,320,558 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523 | $647,711 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | $299,738 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity | $299,738 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Overcoming BTK inhibitor resistance in B-cell malignancies | $299,888 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Overcoming BTK inhibitor resistance in B-cell malignancies | $299,888 | |
| Private capital raised | Form D · SEC | $250,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1245 | DIGITAL PROTEOMICS LLC | — | — |
| 1246 | New England Discovery Partners, LLC | — | — |
| 1247 | TARGUT BIOTECHNOLOGIES INC. | — | — |
| 1248 | SignalRx Pharmaceuticals Inc. | — | $250K |
| 1249 | Tooth Bank, LLC | — | $200K |
| 1250 | EnLiven Therapeutics | — | $140M |
| 1251 | Seurat Therapeutics, Inc. | — | $773K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Guillermo MoralesDirector
- Joel WernickDirector
- Matthew WilliamsDirector · Executive Officer
Patents
- Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitorsgranted
- Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereofgranted
- Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitorsgranted
- Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19application
- Thienopyranones and Furanopyranones as Checkpoint Inhibitors and Modulators of Anti-Tumor Immunitygranted
- Thienopyranones As Kinase And Epigenetic Inhibitorsgranted
- Novel Heterocyclic Compound Classes For Signaling Modulationgranted
- Thienopyranones as Kinase Inhibitorsgranted
- Thienopyranones as Kinase and Epigenetic Inhibitorsapplication
- Thienopyranones as Kinase and Epigenetic Inhibitorsgranted
- Single Molecule Compounds Providing Multi-target Inhibition Of Btk And Other Proteins And Methods Of Use Thereofapplication
- Single Molecule Compounds Providing Multi-target Inhibition Of Parp And Other Proteins And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.